BioNTech R&D Austria

BioNTech R&D Austria is a wholly owned subsidiary of BioNTech SE, focused on the development of novel antibacterial drugs to treat persistent bacterial infections. The development programs are based on the proprietary LysinBuilder platform, which allows the targeted development of precision anti-bacterials. The development pipeline focuses on chronic bacterial infections where antibiotics fail to cure or destroy the natural microbiomes.